TY  - JOUR
AU  - Triulzi, Tiziana
AU  - Bianchini, Giampaolo
AU  - Di Cosimo, Serena
AU  - Pienkowski, Tadeusz
AU  - Im, Young-Hyuck
AU  - Bianchi, Giulia Valeria
AU  - Galbardi, Barbara
AU  - Dugo, Matteo
AU  - De Cecco, Loris
AU  - Tseng, Ling-Ming
AU  - Liu, Mei-Ching
AU  - Bermejo, Begoña
AU  - Semiglazov, Vladimir
AU  - Viale, Giulia
AU  - de la Haba-Rodriguez, Juan
AU  - Oh, Do-Youn
AU  - Poirier, Brigitte
AU  - Valagussa, Pinuccia
AU  - Gianni, Luca
AU  - Tagliabue, Elda
PY  - 2021
DO  - 10.1002/1878-0261.13141
UR  - http://hdl.handle.net/10668/22494
T2  - Molecular oncology
AB  - As most erb-b2 receptor tyrosine kinase 2 (HER2)-positive breast cancer (BC) patients currently receive dual HER2-targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting postsurgical salvage...
LA  - en
KW  - HER2
KW  - breast cancer
KW  - gene expression profile
KW  - pertuzumab
KW  - predictive biomarker
KW  - trastuzumab
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Female
KW  - Humans
KW  - Neoadjuvant Therapy
KW  - Receptor, ErbB-2
KW  - Trastuzumab
KW  - Treatment Outcome
TI  - The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial.
TY  - research article
VL  - 16
ER  -